Cyprumed and MSD signed a nonexclusive license and option agreement to develop oral formulations of MSD’s peptides using Cyprumed’s innovative drug delivery technology.
MSD gains nonexclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets. The agreement also grants MSD the option to exclusively license Cyprumed’s technology for use with individual targets.
Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory, and net sales milestones associated with the approval of any products under the collaboration. Cyprumed may receive additional payments if MSD exercises its exclusive license option.
MSD will be responsible for the research, development, manufacturing, and commercialization of any product utilizing the Cyprumed delivery technology under the agreement.
“Our drug delivery technology has the potential to unlock new opportunities in peptide therapeutics. Continuing this collaboration with MSD to develop our innovative tablet formulations for additional targets is a great validation of our technology,” said Florian Föger, PhD, CEO of Cyprumed.
“We look forward to collaborating with the Cyprumed team to leverage their technology to help advance our macrocyclic peptide development efforts,” added Allen C. Templeton, vice president, pharmaceutical sciences, MSD Research Laboratories.
New CDMO launches
Meribel Pharma Solution, a new mid-size CDMO, has launched with an integrated network across Europe. The firm has ten manufacturing sites and three drug development services sites, situated across France, Spain, and Sweden, following the acquisition of Synerlab Group, a CDMO, and seven European manufacturing facilities from Recipharm last year.
The company, which has expertise in oral solid dose manufacturing, semi-solid dosage formulations, and sterile drug products, has established centers of excellence in drug development, lyophilization, preservative-free multidose technologies, and flexible stick-pack and sachet production.
“There is a gap in the market for a niche-player, mid-sized CDMO that’s focused, agile, and dedicated to solving complex challenges, and we are well positioned to fulfill this unmet need,” said Bruce Vielle, CEO. “We have invested heavily in the latest technologies and expanded our capacity to meet the evolving needs of our customers.”